Timber pharmaceuticals receives fda breakthrough therapy designation for tmb-001 for the treatment of congenital ichthyosis

- company preparing to dose first patients in pivotal phase 3 ascend clinical trial -

TMBR Ratings Summary

TMBR Quant Ranking